Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival : a cohort study (CROSBI ID 207841)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Worm, S.W. ; ... ; Begovac, Josip ; ... Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival : a cohort study // BMC infectious diseases, 13 (2013), 471-1-471-. doi: 10.1186/1471-2334-13-471

Podaci o odgovornosti

Worm, S.W. ; ... ; Begovac, Josip ; ...

engleski

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival : a cohort study

Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Over 176, 775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.

Anti-HIV Agents/therapeutic use; Antiretroviral Therapy; CD4 Lymphocyte Count; HIV Infections/drug therapy/ mortality

Corporate Authors: D:A:D Study Group.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

13

2013.

471-1-471-

objavljeno

1471-2334

10.1186/1471-2334-13-471

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost